Search Results - "Eltrudis, F"

2075 POSTER Does the estrogen receptor status influence survival of pCR breast cancer (BC) patients (pts) after primary chemotherapy (CHT)? Results of a multicenter study by Cazzaniga, M.E, Ionta, M.T, Barni, S, Barca, M, Eltrudis, F, Petrelli, F, Trogu, A, Guerzoni, D, Minerba, L, Massidda, B

Get full text

Adding cisplatin to an anthracycline-based primary chemotherapy in triple-negative (TN) and non-triple negative (non-TN) T4 breast cancer patients (pts): Long-term outcomes by Ionta, M., Atzori, F., Murgia, M., Frau, B., Barca, M., Coinu, A., Trogu, A., Eltrudis, F., Minerba, L., Massidda, B.

“…Abstract only 583 Background: Clinical data demonstrated that standard anthracycline-based chemotherapy may be less beneficial in TN. Conversely, there is…”
Get full text

Outcomes in double-negative (HER2/PR negative) LABC phenotype treated with cisplatin-based primary chemotherapy: Impact of intensified regimen by Ionta, M. T., Atzori, F., Deidda, M. C., Murgia, M., Frau, B., Coinu, A., Barca, M., Eltrudis, F., Minerba, L., Massidda, B.

“…Abstract only 11024 Background: It is widely assumed that HER2-negative and hormone receptors negative tumors (Triple-Negative as TN) are associated with poor…”
Get full text